Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Hierarchical kernel mixture models for the prediction of AIDS disease progression using HIV structural gp120 profiles.

Yoo PD, Shwen Ho Y, Ng J, Charleston M, Saksena NK, Yang P, Zomaya AY.

BMC Genomics. 2010 Dec 2;11 Suppl 4:S22. doi: 10.1186/1471-2164-11-S4-S22.

2.

Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.

Borggren M, Repits J, Kuylenstierna C, Sterjovski J, Churchill MJ, Purcell DF, Karlsson A, Albert J, Gorry PR, Jansson M.

Retrovirology. 2008 Mar 27;5:28. doi: 10.1186/1742-4690-5-28.

3.

Human immunodeficiency virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses.

Baan E, van der Sluis RM, Bakker ME, Bekker V, Pajkrt D, Jurriaans S, Kuijpers TW, Berkhout B, Wolthers KC, Paxton WA, Pollakis G.

J Gen Virol. 2013 Jan;94(Pt 1):20-9. doi: 10.1099/vir.0.046185-0. Epub 2012 Sep 26.

PMID:
23015744
4.

Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, Moldoveanu Z, Elliott MC, Wilson L, Brown R, Jancova D, Barnes S, Vrbkova J, Tomana M, Smith PD, Mestecky J, Renfrow MB, Novak J.

J Biol Chem. 2010 Jul 2;285(27):20860-9. doi: 10.1074/jbc.M109.085472. Epub 2010 May 3.

5.
6.

Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS.

Liu SL, Mittler JE, Nickle DC, Mulvania TM, Shriner D, Rodrigo AG, Kosloff B, He X, Corey L, Mullins JI.

J Virol. 2002 Nov;76(21):10674-84.

7.

HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.

Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Kleeberger CA, Nishanian P, Henrard DR, Phair J.

J Immunol. 1996 Sep 1;157(5):2168-73.

PMID:
8757343
8.

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies.

Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, Cohen MS, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B.

PLoS Comput Biol. 2010 Oct 7;6(10):e1000955. doi: 10.1371/journal.pcbi.1000955.

9.

Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis.

Zagury JF, Bernard J, Achour A, Astgen A, Lachgar A, Fall L, Carelli C, Issing W, Mbika JP, Picard O, et al.

Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7573-7.

12.

Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: persistence of p24 antigen and low T4 cell count.

Eyster ME, Ballard JO, Gail MH, Drummond JE, Goedert JJ.

Ann Intern Med. 1989 Jun 15;110(12):963-9.

PMID:
2567142
13.

Calculation and use of an HIV-1 disease progression score.

Roussanov BV, Taylor JM, Giorgi JV.

AIDS. 2000 Dec 1;14(17):2715-22.

PMID:
11125890
14.
15.

Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

Groenink M, Fouchier RA, Broersen S, Baker CH, Koot M, van't Wout AB, Huisman HG, Miedema F, Tersmette M, Schuitemaker H.

Science. 1993 Jun 4;260(5113):1513-6.

PMID:
8502996
16.

Prediction of co-receptor usage of HIV-1 from genotype.

Dybowski JN, Heider D, Hoffmann D.

PLoS Comput Biol. 2010 Apr 15;6(4):e1000743. doi: 10.1371/journal.pcbi.1000743.

17.

Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

Moss AR, Bacchetti P, Osmond D, Krampf W, Chaisson RE, Stites D, Wilber J, Allain JP, Carlson J.

Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):745-50.

18.

Accurate and efficient gp120 V3 loop structure based models for the determination of HIV-1 co-receptor usage.

Masso M, Vaisman II.

BMC Bioinformatics. 2010 Oct 5;11:494. doi: 10.1186/1471-2105-11-494.

19.

Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.

Virology. 2003 Sep 1;313(2):387-400.

20.

Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion.

Farzadegan H, Henrard DR, Kleeberger CA, Schrager L, Kirby AJ, Saah AJ, Rinaldo CR Jr, O'Gorman M, Detels R, Taylor E, Phair JP, Margolick JB.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15;13(5):448-55.

PMID:
8970472
Items per page

Supplemental Content

Write to the Help Desk